Harmony Biosciences
HRMY
39.34
-0.02
-0.05%
Harmony Biosciences
US · HRMY
#2681 by market cap
Listed 2020
39.34
-0.02
-0.05%
Live - 5344 symbols - heartbeat 2s ago
· 2026-10-08 07:30
Pre-market
39.95
+1.55%
After-hours
39.25
-0.23%
Overnight
38.91
-1.09%
- Market cap
- 2.29B
- P/E (TTM)i
- 12.73
- P/Bi
- 2.29
- EPSi
- 2.71
- Div yieldi
- 0.00%
- 52W posi
- 77%
Reader sentiment
Are you bullish or bearish on HRMY?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.44, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +21.51% YoY
Margins
- Gross margin
- 77.16%
- Operating margin
- 24.00%
- Net margin
- 18.27%
Key ratios & quality
- Enterprise valuei
- 1.68B
- Altman Z-Scorei
- 5.44
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 6.00M | 159.74M | 305.44M | 437.86M | 582.02M | 714.73M | 868.45M |
| Gross profit | 0 | 4.42M | 132.00M | 249.92M | 354.37M | 460.79M | 557.92M | 670.11M |
| Selling & admin expenses | 29.07M | 80.73M | 95.57M | 132.03M | 163.30M | 192.69M | 221.27M | 272.05M |
| Research & development | 12.37M | 69.60M | 19.45M | 30.37M | 70.89M | 76.06M | 145.83M | 189.59M |
| Operating profit | -41.44M | -145.90M | 16.99M | 87.53M | 120.19M | 192.03M | 190.83M | 208.47M |
| Pretax profit | -39.90M | -151.98M | -36.94M | 37.43M | 104.69M | 173.40M | 191.80M | 215.06M |
| Tax | 0 | 0 | 0 | 2.83M | -76.78M | 44.54M | 46.31M | 56.38M |
| Net profit | -39.90M | -151.98M | -36.94M | 34.60M | 181.47M | 128.85M | 145.49M | 158.69M |
| Basic EPS | -1 | -3 | -2 | 1 | 3 | 2 | 3 | 3 |
| Diluted EPS | -1.42 | -3.39 | -2.48 | 0.58 | 2.97 | 2.13 | 2.51 | 2.71 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 184.73M | 200.49M | 239.46M | 243.78M | 215.39M | 261.28M |
| Gross profit | 152.74M | 162.34M | 179.81M | 175.23M | 170.88M | 198.08M |
| Selling & admin expenses | 61.95M | 64.00M | 59.36M | 86.74M | 64.20M | 62.17M |
| Research & development | 34.54M | 50.16M | 54.96M | 49.93M | 69.38M | 46.60M |
| Operating profit | 56.25M | 48.18M | 65.49M | 38.56M | 37.29M | 89.32M |
| Pretax profit | 57.18M | 49.64M | 67.49M | 40.76M | 39.69M | 93.27M |
| Tax | 11.62M | 9.86M | 16.63M | 18.27M | 7.20M | 17.83M |
| Net profit | 45.56M | 39.78M | 50.87M | 22.49M | 32.49M | 75.43M |
| Basic EPS | 1 | 1 | 1 | 0 | 1 | 1 |
| Diluted EPS | 0.78 | 0.68 | 0.87 | 0.38 | 0.55 | 1.28 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 86.68M | 31.50M | 262.89M | 284.44M | 400.29M | 451.07M | 579.25M | 907.01M |
| Cash & ST investments | 83.52M | 24.46M | 228.63M | 234.31M | 323.12M | 353.46M | 467.19M | 775.34M |
| Inventory | 0 | 1.09M | 3.82M | 4.43M | 4.30M | 5.36M | 7.20M | 5.36M |
| Total assets | 89.28M | 106.70M | 427.07M | 433.44M | 673.87M | 811.45M | 999.20M | 1.27B |
| Total current liabilities | 7.23M | 19.89M | 134.54M | 53.78M | 78.88M | 163.78M | 175.08M | 252.13M |
| Short-term debt | -- | -- | -- | 2.00M | 2.00M | 15.00M | 16.25M | 20.00M |
| Long-term debt | -- | 97.95M | 194.25M | 189.98M | 189.65M | 178.57M | 163.02M | 143.66M |
| Total liabilities | 7,754,000.00 | 118,288,000.00 | 329,894,000.00 | 246,936,000.00 | 271,032,000.00 | 344,456,000.00 | 340,045,000.00 | 401,413,000.00 |
| Total equity | 81.53M | -11.59M | 97.18M | 186.51M | 402.84M | 466.99M | 659.16M | 870.22M |
| Retained earnings | -242.67M | -422.86M | -488.20M | -453.60M | -272.13M | -143.28M | 2.22M | 160.90M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 642.69M | 691.35M | 838.80M | 907.01M | 778.82M | 814.33M |
| Cash & ST investments | 506.95M | 565.27M | 672.58M | 775.34M | 640.92M | 667.79M |
| Inventory | 6.38M | 6.10M | 6.88M | 5.36M | 5.28M | 6.36M |
| Total assets | 1.06B | 1.11B | 1.21B | 1.27B | 1.27B | 1.37B |
| Total current liabilities | 175.12M | 180.14M | 223.40M | 252.13M | 217.34M | 234.07M |
| Short-term debt | 17.50M | 18.75M | 20.00M | 20.00M | 20.00M | 20.00M |
| Long-term debt | 158.18M | 153.35M | 148.51M | 143.66M | 138.81M | 133.96M |
| Total liabilities | 335,010,000.00 | 334,928,000.00 | 373,095,000.00 | 401,413,000.00 | 361,475,000.00 | 373,841,000.00 |
| Total equity | 720.53M | 773.08M | 835.12M | 870.22M | 910.35M | 999.24M |
| Retained earnings | 47.78M | 87.55M | 138.42M | 160.90M | 193.39M | 268.82M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -38.80M | -75.44M | -2.99M | 98.56M | 144.47M | 219.39M | 219.82M | 348.20M |
| Depreciation & amortization | 184.00K | 3.21M | 10.24M | 18.84M | 23.39M | 24.36M | 24.11M | 25.34M |
| Free cash flow | -40.14M | -202.59M | -4.99M | -1.74M | 144.29M | 219.08M | 218.67M | 347.89M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -3.20M | 0 | 147.46M | 30.00M | 0 | -100.00M | 0 | 0 |
| Ending cash balance | 84.02M | 25.21M | 229.38M | 235.06M | 244.53M | 311.93M | 453.27M | 752.77M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 33.99M | 79.33M | 108.73M | 126.15M | 27.76M | 92.43M |
| Depreciation & amortization | 5.97M | 5.97M | 5.97M | 7.43M | 5.97M | 5.97M |
| Free cash flow | 33.86M | 79.32M | 108.66M | 126.04M | 27.76M | 92.43M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 489.27M | 546.32M | 647.27M | 752.77M | 589.67M | 550.04M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | 24.39 | 61.58 | 29.63 | 25.84 | 20.75 |
| ROA %i | -78.50 | -155.09 | -23.92 | 8.04 | 32.78 | 17.35 | 16.07 | 13.98 |
| ROIC %i | -- | -- | -- | 16.89 | 39.85 | 21.60 | 19.31 | 16.38 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- | 32.44 |
| EBIT margin %i | -- | -2,433.76 | -5.46 | 20.10 | 27.49 | 33.87 | 29.28 | 26.45 |
| FCF / sales %i | -- | -- | -- | -- | 23.82 | 37.64 | 30.59 | 40.06 |
| Current ratioi | 11.99 | 1.58 | 1.95 | 5.29 | 5.07 | 2.75 | 3.31 | 3.60 |
| Quick ratioi | 11.55 | 1.44 | 1.86 | 5.01 | 4.79 | 2.61 | 3.14 | 3.46 |
| Debt / assetsi | -- | 91.79 | 45.48 | 44.29 | 28.44 | 23.85 | 17.94 | 12.87 |
| LT debt / equityi | -- | -- | 199.89 | 101.86 | 47.08 | 38.24 | 24.73 | 16.51 |
| Interest coveragei | -- | -- | -0.31 | 2.56 | 7.68 | 8.30 | 11.96 | 15.68 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | 318.00 | 53.88 | 32.76 | 25.64 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | 61.41 | -4.37 |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | 34.09 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 24.71 | 27.58 | 25.93 | 20.75 | 17.86 | 20.46 |
| ROA %i | 16.05 | 18.40 | 17.38 | 13.98 | 12.51 | 14.61 |
| ROIC %i | 18.84 | 21.31 | 20.35 | 16.38 | 14.17 | 16.49 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 28.73 | 31.22 | 29.76 | 26.45 | 23.54 | 26.53 |
| FCF / sales %i | 29.72 | 33.49 | 35.95 | 40.06 | 38.01 | 36.97 |
| Current ratioi | 3.67 | 3.84 | 3.75 | 3.60 | 3.58 | 3.48 |
| Quick ratioi | 3.50 | 3.65 | 3.46 | 3.46 | 3.45 | 3.33 |
| Debt / assetsi | 16.64 | 15.53 | 13.95 | 12.87 | 12.49 | 11.21 |
| LT debt / equityi | 21.95 | 19.84 | 17.78 | 16.51 | 15.25 | 13.41 |
| Interest coveragei | 12.74 | 15.04 | 16.05 | 15.68 | 15.07 | 18.91 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Net product revenue100.00%
Quote time 2026-10-08 07:30:11 · For reference only, not investment advice and not tailored to your situation.